Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hai… Read more
Genomma Lab Internacional S.A.B. de C.V (GNMLF) - Total Assets
Latest total assets as of June 2025: $24.24 Billion USD
Based on the latest financial reports, Genomma Lab Internacional S.A.B. de C.V (GNMLF) holds total assets worth $24.24 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genomma Lab Internacional S.A.B. de C.V - Total Assets Trend (2013–2024)
This chart illustrates how Genomma Lab Internacional S.A.B. de C.V’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genomma Lab Internacional S.A.B. de C.V - Asset Composition Analysis
Current Asset Composition (December 2024)
Genomma Lab Internacional S.A.B. de C.V's total assets of $24.24 Billion consist of 1093.0% current assets and -993.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 215.5% |
| Accounts Receivable | $4.61 Billion | 417.5% |
| Inventory | $2.18 Billion | 197.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $284.24 Million | 25.8% |
| Goodwill | $4.36 Million | 0.4% |
Asset Composition Trend (2013–2024)
This chart illustrates how Genomma Lab Internacional S.A.B. de C.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genomma Lab Internacional S.A.B. de C.V's current assets represent 1093.0% of total assets in 2024, an increase from 57.6% in 2013.
- Cash Position: Cash and equivalents constituted 215.5% of total assets in 2024, up from 10.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, a decrease from 27.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 417.5% of total assets.
Genomma Lab Internacional S.A.B. de C.V Competitors by Total Assets
Key competitors of Genomma Lab Internacional S.A.B. de C.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Genomma Lab Internacional S.A.B. de C.V - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Genomma Lab Internacional S.A.B. de C.V generates 0.81x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Genomma Lab Internacional S.A.B. de C.V generates $ 135.25 in net profit.
Genomma Lab Internacional S.A.B. de C.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.83 | 1.96 | 1.77 |
| Quick Ratio | 1.54 | 1.54 | 1.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.02 Billion | $ 321.18 Million | $ 5.13 Billion |
Genomma Lab Internacional S.A.B. de C.V - Advanced Valuation Insights
This section examines the relationship between Genomma Lab Internacional S.A.B. de C.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -9.3% |
| Total Assets | $1.10 Billion |
| Market Capitalization | $808.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genomma Lab Internacional S.A.B. de C.V's assets below their book value (0.73 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genomma Lab Internacional S.A.B. de C.V's assets decreased by 9.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genomma Lab Internacional S.A.B. de C.V (2013–2024)
The table below shows the annual total assets of Genomma Lab Internacional S.A.B. de C.V from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.10 Billion | -9.26% |
| 2023-12-31 | $1.22 Billion | +9.82% |
| 2022-12-31 | $1.11 Billion | +5.61% |
| 2021-12-31 | $1.05 Billion | -2.06% |
| 2020-12-31 | $1.07 Billion | +5.04% |
| 2019-12-31 | $1.02 Billion | +11.08% |
| 2018-12-31 | $917.92 Million | +13.05% |
| 2017-12-31 | $811.92 Million | +6.48% |
| 2016-12-31 | $762.50 Million | -25.32% |
| 2015-12-31 | $1.02 Billion | -95.98% |
| 2014-12-31 | $25.43 Billion | +46.54% |
| 2013-12-31 | $17.35 Billion | -- |